# The Norwegian Immunotherapy in Multiple Myeloma Study

> **NCT06855121** · — · RECRUITING · sponsor: **St. Olavs Hospital** · enrollment: 400 (estimated)

## Conditions studied

- Myeloma Multiple
- Plasma Cell Leukemia
- AL Amyloidosis

## Interventions

- **DRUG:** Teclistamab
- **DRUG:** Elranatamab
- **BIOLOGICAL:** Ciltacabtagene Autoleucel
- **DRUG:** Talquetamab
- **BIOLOGICAL:** Idecabtagene vicleucel

## Key facts

- **NCT ID:** NCT06855121
- **Lead sponsor:** St. Olavs Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2029-01
- **Final completion:** 2037-12-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-03-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06855121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06855121, "The Norwegian Immunotherapy in Multiple Myeloma Study". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06855121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*